Physicians' Academy for Cardiovascular Education
This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.
This study showed that the most frequent first manifestations of CV- and renal disease in T2DM patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.
The phase III DAPA-CKD trial evaluating the efficacy of SGLT2 inhibitor dapagliflozin in patients with CKD will be stopped early due to overwhelming benefit.
In a healthy adult population, higher protein intake was associated with renal hyperfiltration and rapid decline of eGFR compared to those taking lowest protein intake. With poll
This e-learning module addresses the effects of SGLT2 inhibition in cardiorenal syndrome. Member registration (free) is needed to enroll in this course.
This e-learning course focusses on the effect of GLP-1RAs on kidney outcomes in diabetes patients. Member registration (free) is needed to enroll in this course.
The CVD-REAL 3 study assessed the rate of eGFR decline and other kidney outcomes in T2DM patients who started SGLT2i treatment compared with other glucose-lowering agents
This video series addresses the effect of SGLT2i on kidney outcomes in diabetes patients with chronic kidney disease (CKD). Member registration (free) is needed to enroll in this course.
AHA 2019 The CKD substudy of the ISCHEMIA trial showed that an initial invasive strategy did not improve clinical outcomes, nor angina symptoms and QoL in patients with CKD and SIHD.
AHA 2019 The ISCHEMIA-CKD trial evaluated whether there is a benefit of adding coronary angiogrpahy and revascularization to OMT in patients with advanced CKD and at least moderate ischemia.
A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.
A systematic review and meta-analysis of four trials shows that SGLT2 inhibition reduces the risk for dialysis, kidney transplantation, or death due to kidney disease in T2DM patients.
